Effect of intensive LDL cholesterol lowering with PCSK9 monoclonal antibodies on tendon xanthoma regression in familial hypercholesterolemia
Bea, A.M. ; Perez-Calahorra, S. ; Marco-Benedi, V. ; Lamiquiz-Moneo, I. ; Jarauta, E. (Universidad de Zaragoza) ; Mateo Gallego, R. (Universidad de Zaragoza) ; Civeira, F. (Universidad de Zaragoza)
Resumen: Background and aims: The effect of LDLc lowering with PCSK9 antibodies on tendon xanthomas (TX) is unknown.
Methods: TX was measured in 24 heterozygous familial hypercholesterolemia (HeFH) cases and in 24 HeFH controls with or without PCSK9 inhibitors for at least one year.
Results: Exposure to PCSK9 inhibitors in cases was 2.96 ± 1.33 years. LDLc decreased 80.8 ± 7.66% in cases and 56.9 ± 11.1% in controls. There was a decrease in maximum (-5.03%) and mean (-5.32%) TX in cases but not in controls (+3.97%, +3.16, respectively, p = 0.01). PCSK9 inhibitor treatment was independently associated with TX reduction.
Conclusion: Addition of a PCSK9 inhibitor to statin and ezetimibe resulted in a greater decrease in LDLc and TX after 3 years of treatment.
Idioma: Inglés
DOI: 10.1016/j.atherosclerosis.2017.06.009
Año: 2017
Publicado en: Atherosclerosis 263 (2017), 92-96
ISSN: 0021-9150
Factor impacto JCR: 4.467 (2017)
Categ. JCR: PERIPHERAL VASCULAR DISEASE rank: 9 / 65 = 0.138 (2017) - Q1 - T1
Categ. JCR: CARDIAC & CARDIOVASCULAR SYSTEMS rank: 34 / 128 = 0.266 (2017) - Q2 - T1
Factor impacto SCIMAGO: 1.967 - Cardiology and Cardiovascular Medicine (Q1)
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/IIS16-0114
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/PIE16-00022
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI15-01983
Tipo y forma: Article (PostPrint)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material.
Exportado de SIDERAL (2024-01-24-14:59:51)
Visitas y descargas
Methods: TX was measured in 24 heterozygous familial hypercholesterolemia (HeFH) cases and in 24 HeFH controls with or without PCSK9 inhibitors for at least one year.
Results: Exposure to PCSK9 inhibitors in cases was 2.96 ± 1.33 years. LDLc decreased 80.8 ± 7.66% in cases and 56.9 ± 11.1% in controls. There was a decrease in maximum (-5.03%) and mean (-5.32%) TX in cases but not in controls (+3.97%, +3.16, respectively, p = 0.01). PCSK9 inhibitor treatment was independently associated with TX reduction.
Conclusion: Addition of a PCSK9 inhibitor to statin and ezetimibe resulted in a greater decrease in LDLc and TX after 3 years of treatment.
Idioma: Inglés
DOI: 10.1016/j.atherosclerosis.2017.06.009
Año: 2017
Publicado en: Atherosclerosis 263 (2017), 92-96
ISSN: 0021-9150
Factor impacto JCR: 4.467 (2017)
Categ. JCR: PERIPHERAL VASCULAR DISEASE rank: 9 / 65 = 0.138 (2017) - Q1 - T1
Categ. JCR: CARDIAC & CARDIOVASCULAR SYSTEMS rank: 34 / 128 = 0.266 (2017) - Q2 - T1
Factor impacto SCIMAGO: 1.967 - Cardiology and Cardiovascular Medicine (Q1)
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/IIS16-0114
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/PIE16-00022
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI15-01983
Tipo y forma: Article (PostPrint)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material. Exportado de SIDERAL (2024-01-24-14:59:51)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles > Artículos por área > Medicina
Record created 2024-01-24, last modified 2024-01-24